Expression of biliary antigen and its clinical significance in hepatocellular carcinoma

被引:18
|
作者
Yoon, DS
Jeong, J
Park, YN
Kim, KS
Kwon, SW
Chi, HS
Park, C
Kim, BR
机构
[1] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea
[3] Kwandong Univ, Coll Med, Dept Surg, Kangnung, South Korea
[4] Pochon CHA Univ, Coll Med, Dept Surg, Kyungkido, South Korea
关键词
hepatocellular carcinoma; biliary antigen; clinical significance;
D O I
10.3349/ymj.1999.40.5.472
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to classify the hepatocellular carcinomas (HCCs) which had diverse clinicopathologic characteristics, we divided HCCs into two groups according to the expression of biliary antigen on the basis of the hypothesis that the hepatocyte and biliary epithelial cell originate from the same precursor cell, and then we investigated the clinical and pathologic characteristics in the two groups. Forty HCC cases with no preoperative treatment and at least two-year follow-up data were selected among 202 cases of HCC files from 1991 to 1995. Expression of biliary antigen (AE1, cytokeratin 19), p53, AFP, and Ki-67 in the tumor tissue were assessed by immunohistochemistry. Positive cytokeratin 19 was noted in one case (2.5%); AE1 was detected in 40% of patients; p53 was overexpressed in 20% of patients; and AFP was detected in 45% of patients. No statistical difference between the biliary antigen positive group (16 cases) and the negative group (24 cases) were noted in terms of mean age, sex, presurgical serum AFP level, Child class, and tumor size. HBsAg positive race was 66.7% for the biliary antigen (-) group and 93.8% for the biliary antigen (+) group with a statistically significant difference (p=0.048). The number of cases for Edmonson-Steiner grade I/II and III/IV were 15 and 9 in the biliary antigen (-) group, and 4 and 12 in the biliary antigen (+) group, respectively, with a statistically significant difference (p=0.024). The 1, 3 and 5-year disease-free survival races were 69.7, 40.9 and 40.9% for the biliary antigen (-) group and 73.7, 39.1, 39.1% for the biliary antigen (+) group with no statistically significant difference. The 1, 3 and 5-year overall survival rates were 91.7, 73.8, 66.4% for the biliary antigen (-) group and 68.8, 34.4, 34.4% for the biliary antigen (+) group, with a significantly greater overall survival rate for the biliary antigen negative group (p=0.045). Poor histopathological differentiation, a high HBsAg positive rate and poor overall survival rate were noted in the biliary antigen positive group and the differences were statistically significant. In conclusion, HCCs with positive biliary antigen, which originates from more primitive cells, is suggested to he more aggressive than HCCs with negative biliary antigen.
引用
收藏
页码:472 / 477
页数:6
相关论文
共 50 条
  • [1] Biliary differentiation and its clinical significance in hepatocellular carcinoma.
    Park, YN
    Yoon, DS
    Chi, HS
    Park, CI
    HEPATOLOGY, 1998, 28 (04) : 736A - 736A
  • [2] Clinical significance of the expression of melanoma antigen (MAGE) genes in hepatocellular carcinoma
    Tsujitani, S
    Suzuki, K
    Kaibara, N
    CANCER GENE THERAPY, 1999, 6 (06) : S32 - S32
  • [3] The expression of Heparanase mRNA and its clinical significance in Hepatocellular carcinoma
    Wang, Qiang
    Shen, Yu
    Wang, Peng
    Li, Xiaowei
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2013, 9 (02) : 250 - 252
  • [4] The expression of SALL4 and its clinical significance in hepatocellular carcinoma
    Xin, Z.
    Gao, H.
    Jin, Q.
    Niu, J.
    Wen, X.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S627 - S628
  • [5] Expression of VAT1 in hepatocellular carcinoma and its clinical significance
    Heng, Wang
    Wei, Fei
    Li, Wanhai
    Li, Qian
    Xiong, Dan-Lei
    Ma, Ying-Yu
    Zhang, Da-Hong
    NEOPLASMA, 2021, 68 (02) : 416 - 422
  • [6] Expression of NEDD9 in hepatocellular carcinoma and its clinical significance
    Lu, Peng
    Wang, Zhi-Peng
    Dang, Zheng
    Zheng, Zhi-Gang
    Li, Xiao
    Zhou, Liang
    Ding, Rui
    Yue, Shu-Qiang
    Dou, Ke-Feng
    ONCOLOGY REPORTS, 2015, 33 (05) : 2375 - 2383
  • [7] The Expression of SALL4 and Its Clinical Significance In Hepatocellular Carcinoma
    Xin, Zhiying
    Wen, Xiaoyu
    Jin, Qinlong
    Niu, Junqi
    HEPATOLOGY, 2016, 64 : 670A - 670A
  • [8] Low expression level of Dickkopf 4 in hepatocellular carcinoma and its clinical significance
    Cui, Dan
    Wang, Zhi
    Wang, Tao
    Tang, Xiaoyin
    Zhai, Bo
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (01): : 760 - 769
  • [9] Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance
    Wu, Jingdong
    Yang, Yongfei
    Song, Jiansheng
    ONCOLOGY LETTERS, 2020, 20 (05)
  • [10] Expression of WTX gene in hepatocellular carcinoma and cell lines and its clinical significance
    Liao, Chuanwen
    Hu, Shuqin
    Song, Zhi
    Cao, Hong
    Shi, Jun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (02): : 1794 - 1799